| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Sang-We Kim | |
| Dae Ho Lee | |||
| Shinkyo Yoon | |||
| P2860 | cites work | Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 |
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs | Q34175045 | ||
| Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto | Q35568485 | ||
| The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis | Q36287297 | ||
| Radiation as an immunological adjuvant: current evidence on dose and fractionation. | Q36347177 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| The PD-1-PD-L pathway in immunological tolerance | Q36405777 | ||
| Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment | Q37268974 | ||
| Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports | Q37582620 | ||
| Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives | Q38645803 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Treatment of Locally Advanced Non-Small Cell Lung Cancer | Q39027412 | ||
| Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). | Q39030907 | ||
| Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial | Q40358678 | ||
| Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | Q40534742 | ||
| Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression | Q40877587 | ||
| Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies | Q41011622 | ||
| Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death | Q42115292 | ||
| Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology | Q46253129 | ||
| Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | Q46672565 | ||
| Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol | Q50436863 | ||
| P433 | issue | 10 | |
| P921 | main subject | etoposide | Q418817 |
| P304 | page(s) | 3525-3528 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). | |
| P478 | volume | 9 |
Search more.